Bradley L. Campbell is the President and Chief Executive Officer and a Director of Amicus Therapeutics (NASDAQ: FOLD) a global biotechnology company focused on developing and delivering transformative medicines for people living with rare diseases. He brings more than 20 years of experience in the Orphan Drug industry. Mr. Campbell joined Amicus in 2006 and was most recently the President and COO responsible for the global commercialization of Galafold^®. During his tenure, he also led the Business Development, Technical Operations, Market Access and Program Management functions among others.

Mr. Campbell currently serves on a number of Boards including the Advisory Board of the Duke Margolis Institute for Health Policy, the Biotechnology Innovation Organization, and the Corporate Advisory Board for the National Tay-Sachs and Allied Diseases Association. He previously served on the Board of Progenics Pharmaceuticals (NASDAQ: PGNX) from 2016 until its successful acquisition by Lantheus Holdings in 2020, as well as ARYA Sciences Acquisition Corp III, and Gennao Bio.

Prior to Amicus, Mr. Campbell spent time in various commercial and business development roles at Genzyme and Bristol-Myers Squibb and as a strategy consultant for Marakon Associates.  He received a B.A. in Public Policy Studies from Duke University and an M.B.A. from Harvard Business School.